Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

LAURA FERRIS

NPI
1043283229
CMS profile
183114
Location
PITTSBURGH, PA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2024 · Entire year

$135,900.11

122 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2024 · entire year · sorted by reported total

By paying entity

PY2024 · entire year · sorted by reported total

Page 3 of 3; records 101–122 of 122 matching records. This page contains 22 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

LAURA FERRIS

NPI 1043283229 · CMS profile ID 183114

PITTSBURGH, PA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 3 of 3; records 101–122 of 122 matching records. This page contains 22 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1043283229?year=2024&recipient=provider&page=3#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
LAURA FERRIS, NPI 1043283229, CMS profile ID 183114. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 3; records 101–122 of 122 matching records. This page contains 22 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1043283229?year=2024&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
APA 7
IndustryPayments. (2026). LAURA FERRIS, NPI 1043283229, CMS profile ID 183114. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 3; records 101–122 of 122 matching records. This page contains 22 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1043283229?year=2024&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
Bluebook
LAURA FERRIS, NPI 1043283229, CMS profile ID 183114, IndustryPayments, General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 3 of 3; records 101–122 of 122 matching records. This page contains 22 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff. https://industrypayments.org/provider/npi-1043283229?year=2024&recipient=provider&page=3#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2024

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2024 · Physicians and non-physician practitioners · CMS publication 2026-06-30

122 matching records · $135,900.11 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 122 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 101–122 of 122.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Regeneron Healthcare Solutions, Inc. $31.1802/10/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1114047132 CMS
E.R. Squibb & Sons, L.L.C. $4,200.0002/08/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1101300129 CMS
E.R. Squibb & Sons, L.L.C. $4,200.0002/08/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1101300131 CMS
E.R. Squibb & Sons, L.L.C. $124.9902/08/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1101300197 CMS
E.R. Squibb & Sons, L.L.C. $712.1202/08/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1101300199 CMS
Lilly USA, LLC $14.8602/08/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1135145963 CMS
E.R. Squibb & Sons, L.L.C. $5,840.0001/30/2024 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1101300123 CMS
Amgen Inc. $2,920.0001/26/2024 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1117250519 CMS
E.R. Squibb & Sons, L.L.C. $134.2601/25/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1101300127 CMS
ABBVIE INC. $2,025.0001/24/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1103150109 CMS
E.R. Squibb & Sons, L.L.C. $125.8201/24/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1101300125 CMS
GENZYME CORPORATION $3,343.0001/23/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1140004720 CMS
ABBVIE INC. $25.3101/19/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1103724656 CMS
Novartis Pharmaceuticals Corporation $49.2601/14/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1086783421 CMS
Verrica Pharmaceuticals Inc. $79.6501/14/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1118380354 CMS
Amgen Inc. $71.1101/13/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1117250521 CMS
ABBVIE INC. $2,025.0001/10/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1103150107 CMS
ABBVIE INC. $1.5801/10/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1103724652 CMS
ABBVIE INC. $5.9601/10/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1103724654 CMS
E.R. Squibb & Sons, L.L.C. $123.6601/10/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1101300167 CMS
PFIZER INC. $15.2701/10/2024 Education No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1131910016 CMS
PFIZER INC. $12,400.0001/02/2024 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1131616726 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $45,061.75 77
PY2020 $19,037.53 12
PY2021 $23,803.98 37
PY2022 $57,823.61 104
PY2023 $135,657.33 201
PY2024 $135,900.11 122
PY2025 $84,498.97 82

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Recipient $1,735.52 7
PY2025 Principal investigator $147,066.62 20
PY2024 Principal investigator $350,434.74 72
PY2023 Recipient $1,749.69 9
PY2023 Principal investigator $378,357.55 136
PY2022 Recipient $340.00 1
PY2022 Principal investigator $495,035.39 92
PY2021 Principal investigator $555,852.33 99
PY2020 Recipient $1,966.04 2
PY2020 Principal investigator $684,617.56 107
PY2019 Recipient $15,148.85 12
PY2019 Principal investigator $1,180,310.47 100

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

27 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Recipient Regeneron Pharmaceuticals, Inc. $506.21 12/11/2025 Covered Recipient Physician A Phase 3 Randomized Study of Intralesional Cemiplimab Versus Primary Surgery in Participants With Early Stage Cutaneous Squamous Cell Carcinoma (CSCC) No dispute reported 06/30/2026 1184117479
Recipient Regeneron Pharmaceuticals, Inc. $211.48 12/11/2025 Covered Recipient Physician A Phase 3 Randomized Study of Intralesional Cemiplimab Versus Primary Surgery in Participants With Early Stage Cutaneous Squamous Cell Carcinoma (CSCC) No dispute reported 06/30/2026 1184117481
Recipient Regeneron Pharmaceuticals, Inc. $87.12 12/11/2025 Covered Recipient Physician A Phase 3 Randomized Study of Intralesional Cemiplimab Versus Primary Surgery in Participants With Early Stage Cutaneous Squamous Cell Carcinoma (CSCC) No dispute reported 06/30/2026 1184117483
Recipient Regeneron Pharmaceuticals, Inc. $30.42 12/11/2025 Covered Recipient Physician A Phase 3 Randomized Study of Intralesional Cemiplimab Versus Primary Surgery in Participants With Early Stage Cutaneous Squamous Cell Carcinoma (CSCC) No dispute reported 06/30/2026 1184117485
Recipient Regeneron Pharmaceuticals, Inc. $76.06 12/11/2025 Covered Recipient Physician A Phase 3 Randomized Study of Intralesional Cemiplimab Versus Primary Surgery in Participants With Early Stage Cutaneous Squamous Cell Carcinoma (CSCC) No dispute reported 06/30/2026 1184117487
Recipient Regeneron Pharmaceuticals, Inc. $55.31 12/11/2025 Covered Recipient Physician A Phase 3 Randomized Study of Intralesional Cemiplimab Versus Primary Surgery in Participants With Early Stage Cutaneous Squamous Cell Carcinoma (CSCC) No dispute reported 06/30/2026 1184117489
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $7,516.08 11/03/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF NORTH CAROLINA HOSP.
TAK-279-PsO-3004 A Phase 3, multi-center, head to head Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1223272623
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $5,364.00 11/03/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF NORTH CAROLINA HOSP.
TAK-279-PsO-3004 A Phase 3, multi-center, head to head Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1223272625
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $5,313.00 11/03/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF NORTH CAROLINA HOSP.
TAK-279-PsO-3004 A Phase 3, multi-center, head to head Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1223272627
Recipient Regeneron Pharmaceuticals, Inc. $768.92 10/29/2025 Covered Recipient Physician A Phase 3 Randomized Study of Intralesional Cemiplimab Versus Primary Surgery in Participants With Early Stage Cutaneous Squamous Cell Carcinoma (CSCC) No dispute reported 06/30/2026 1184117477
Principal investigator 1 Janssen Research & Development, LLC $3,922.00 10/23/2025 Non-covered Recipient Entity
Univ Of Pittsburgh Physicians
A Multicenter, Open Registry of Patients With Plaque Psoriasis Who Are Candidates for Systemic Therapy Including Biologics No dispute reported 06/30/2026 1175267680
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $20,000.00 09/05/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF NORTH CAROLINA HOSP.
TAK-279-PsO-3004 A Phase 3, multi-center, head to head Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1223272615
Principal investigator 1 Janssen Research & Development, LLC $10,981.60 07/31/2025 Non-covered Recipient Entity
Univ Of Pittsburgh Physicians
A Multicenter, Open Registry of Patients With Plaque Psoriasis Who Are Candidates for Systemic Therapy Including Biologics No dispute reported 06/30/2026 1175267883
Principal investigator 1 Arcutis Biotherapeutics, Inc. $22,465.13 07/11/2025 Non-covered Recipient Entity
UPMC Department of Dermatology Clinical Trials
A Phase 1b, Randomized, Vehicle-Controlled, Double-Blind, Pharmacokinetics, Pharmacodynamics, and Safety Study of ARQ-255 Topical Suspension in Healthy Volunteers and Subjects with Alopecia Areata No dispute reported 06/30/2026 1248163836
Principal investigator 1 Arcutis Biotherapeutics, Inc. $2,777.50 07/02/2025 Non-covered Recipient Entity
UPMC Department of Dermatology Clinical Trials
A Phase 1b, Randomized, Vehicle-Controlled, Double-Blind, Pharmacokinetics, Pharmacodynamics, and Safety Study of ARQ-255 Topical Suspension in Healthy Volunteers and Subjects with Alopecia Areata No dispute reported 06/30/2026 1248163832
Principal investigator 1 Arcutis Biotherapeutics, Inc. $7,134.33 07/02/2025 Non-covered Recipient Entity
UPMC Department of Dermatology Clinical Trials
A Phase 1b, Randomized, Vehicle-Controlled, Double-Blind, Pharmacokinetics, Pharmacodynamics, and Safety Study of ARQ-255 Topical Suspension in Healthy Volunteers and Subjects with Alopecia Areata No dispute reported 06/30/2026 1248163834
Principal investigator 1 Janssen Research & Development, LLC $5,490.80 05/08/2025 Non-covered Recipient Entity
Univ Of Pittsburgh Physicians
A Multicenter, Open Registry of Patients With Plaque Psoriasis Who Are Candidates for Systemic Therapy Including Biologics No dispute reported 06/30/2026 1175267870
Principal investigator 1 Amgen Inc. $31,805.00 04/24/2025 Non-covered Recipient Entity
UNIVERSITY OF PITTSBURGH MEDICAL CENTER
A Phase 3, Multicenter, Double-blind Maintenance Study to Assess Long-term Safety, Tolerability, and Efficacy of Rocatinlimab in Adult and Adolescent Subjects With Moderate-to-severe Atopic Dermatitis (AD) (ROCKET-ASCEND) No dispute reported 06/30/2026 1246650717
Principal investigator 1 Janssen Research & Development, LLC $2,411.66 04/23/2025 Non-covered Recipient Entity
Univ Of Pittsburgh Physicians
A Multicenter, Open Registry of Patients With Plaque Psoriasis Who Are Candidates for Systemic Therapy Including Biologics No dispute reported 06/30/2026 1175267928
Principal investigator 1 Incyte Corporation $854.24 04/09/2025 Non-covered Recipient Entity
UPMC
An Open-Label, Single-Arm, Phase 4 Study of Ruxolitinib Cream in Adults With Atopic Dermatitis Experiencing Sleep Disturbance in the United States (MORPHEUS) No dispute reported 06/30/2026 1240609201
Principal investigator 1 Incyte Corporation $2,465.00 03/24/2025 Non-covered Recipient Entity
UNIVERSITY OF PITTSBURGH MEDICAL CENTER UPMC DERMATOLOGY CLINIC OAKLAND FALK MEDICAL BUILDING
A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, EfficacyAnd Safety of Ruxolitinib Cream in Participants with Prurigo Nodularis No dispute reported 06/30/2026 1240608714
Principal investigator 1 Incyte Corporation $1,607.50 03/24/2025 Non-covered Recipient Entity
UNIVERSITY OF PITTSBURGH MEDICAL CENTER UPMC DERMATOLOGY CLINIC OAKLAND FALK MEDICAL BUILDING
A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, EfficacyAnd Safety of Ruxolitinib Cream in Participants with Prurigo Nodularis No dispute reported 06/30/2026 1240608718
Principal investigator 1 Eli Lilly and Company $1,230.27 03/10/2025 Non-covered Recipient Entity
UNIVERSITY OF PITTSBURGH
A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, OPERATIONALLY SEAMLESS, ADAPTIVE PHASE 2/3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF BARICITINIB IN ADULT PATIENTS WITH SEVERE OR VERY SEVERE ALOPECIA AREATA No dispute reported 06/30/2026 1187892402
Principal investigator 1 Incyte Corporation $1,683.90 01/27/2025 Non-covered Recipient Entity
UNIVERSITY OF PITTSBURGH MEDICAL CENTER UPMC DERMATOLOGY CLINIC OAKLAND FALK MEDICAL BUILDING
A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, EfficacyAnd Safety of Ruxolitinib Cream in Participants with Prurigo Nodularis No dispute reported 06/30/2026 1240608710
Principal investigator 1 Janssen Research & Development, LLC $10,676.81 01/21/2025 Non-covered Recipient Entity
Univ Of Pittsburgh Physicians Dept Of Neurosurgery
A Multicenter, Open Registry of Patients With Plaque Psoriasis Who Are Candidates for Systemic Therapy Including Biologics No dispute reported 06/30/2026 1175267913
Principal investigator 1 Incyte Corporation $1,496.80 01/06/2025 Non-covered Recipient Entity
UNIVERSITY OF PITTSBURGH MEDICAL CENTER UPMC DERMATOLOGY CLINIC OAKLAND FALK MEDICAL BUILDING
A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, EfficacyAnd Safety of Ruxolitinib Cream in Participants with Prurigo Nodularis No dispute reported 06/30/2026 1240608722
Principal investigator 1 Incyte Corporation $1,871.00 01/06/2025 Non-covered Recipient Entity
UNIVERSITY OF PITTSBURGH MEDICAL CENTER UPMC DERMATOLOGY CLINIC OAKLAND FALK MEDICAL BUILDING
A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, EfficacyAnd Safety of Ruxolitinib Cream in Participants with Prurigo Nodularis No dispute reported 06/30/2026 1240608726